Trinity Biotech (TRIB) Common Equity (2009 - 2025)

Trinity Biotech's Common Equity history runs 17 years deep, the most recent figure standing at -$72.0 million for Q4 2025.

• In Q4 2025, Common Equity fell 104.6% year-over-year to -$72.0 million; the TTM figure through Dec 2025 stood at -$72.0 million (down 104.6% YoY), while the FY2025 annual figure was -$72.0 million, down 104.6% from the prior year.
• Common Equity came in at -$72.0 million for Q4 2025 at Trinity Biotech, down from -$49.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$127000.0 in Q1 2021 to a low of -$496.0 million in Q2 2021.
• A 5-year average of -$56.7 million and a median of -$23.4 million in 2023 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 85.62% in 2021 and fell as far as 69562.92% in 2021.
• Trinity Biotech's Common Equity stood at -$319000.0 in 2021, then slumped by 582.13% to -$2.2 million in 2022, then sank by 1000.6% to -$23.9 million in 2023, then tumbled by 46.9% to -$35.2 million in 2024, then tumbled by 104.6% to -$72.0 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered -$72.0 million, -$49.5 million, and -$35.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison